Abiopharma

🔍 Davidson Michael H. (Executive)

Company: NewAmsterdam Pharma Co N.V. (NAMS)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Sold 11,582 shares of Ordinary Shares (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: false | shares_owned_after: 378,859.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 81,000 shares of Ordinary Shares (Direct)
  Date: 2026-01-07 | Code: A | equity_swap_involved: false | shares_owned_after: 459,859.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Acquired 364,000 shares of Option (right to buy) at $35.45 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2036-01-07 | equity_swap_involved: false | shares_owned_after: 364,000.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• F3: Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
• F4: Each RSU was granted on January 7, 2026 for no consideration.
• F5: 25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.